Evidence map›Paper›PMID 37046759›Full record

ArticleCancers2023

Diagnostic Performance of Afirma and Interpace Diagnostics Genetic Testing in Indeterminate Thyroid Nodules: A Single Center Study.

Emad Kandil, Tyler A Metz, Peter P Issa, Mohamed Aboueisha, Mahmoud Omar, Abdallah S Attia, Bert Chabot, Mohammad Hussein, Krzysztof Moroz, Mohamed Shama and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Emad KandilDepartment of Surgery, Tulane University School of Medicine, New Orleans, LA 70112, USA.
Tyler A MetzTulane University School of Medicine, New Orleans, LA 70112, USA.ORCID 0009-0006-2752-8931
Peter P IssaSchool of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.ORCID 0000-0002-5248-3142
Mohamed AboueishaDepartment of Surgery, Tulane University School of Medicine, New Orleans, LA 70112, USA.
Mahmoud OmarDepartment of Surgery, Tulane University School of Medicine, New Orleans, LA 70112, USA.
Abdallah S AttiaDepartment of Surgery, Tulane University School of Medicine, New Orleans, LA 70112, USA.
Bert ChabotTulane University School of Medicine, New Orleans, LA 70112, USA.
Mohammad HusseinDepartment of Surgery, Tulane University School of Medicine, New Orleans, LA 70112, USA.
Krzysztof MorozDepartment of Pathology, Tulane University School of Medicine, New Orleans, LA 70112, USA.
Mohamed ShamaDepartment of Surgery, Tulane University School of Medicine, New Orleans, LA 70112, USA.
Eman ToraihDepartment of Surgery, Tulane University School of Medicine, New Orleans, LA 70112, USA.ORCID 0000-0001-9267-3787
Tulane University · USSuez Canal University · EGLouisiana State University Health Sciences Center New Orleans · US

Funding

American Thyroid Association THYROIDGRANT2021-0000000232Tulane University School of Medicine Pilot GrantTulane University The Tulane University Bridge Fund
6 · The paper itself

Abstract

Indeterminate thyroid nodules (ITN) represent 20-30% of biopsied nodules, with a 10-60% risk of malignancy. Molecular testing can stratify the risk of malignancy among ITNs, and subsequently reduce the need for unnecessary diagnostic surgery. We aimed to assess the performance of these molecular tests at a single institution. Patients with Bethesda III, IV, and V nodules with Afirma and Interpace Diagnostics genetic testing data from November 2013 to November 2021 were included. Three cohorts were formed, including GSC + XA, ThyGeNEXT + ThyraMIR, and GSC + GEC. Statistical analysis determined the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), diagnostic odds ratio (DOR), and accuracy of each type of testing. The PPV of nodules undergoing genetic testing by ThyGeNEXT + ThyraMIR (45.00%, 95%CI: 28.28-62.93%,

Indexed as

Afirmagenetic testingindeterminate thyroid nodulesInterpace Diagnosticstatistical measures

Identifiers

PMID37046759
PMCPMC10093254
OpenAlexW4361267913

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.